Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,485 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Study Group.
Borkhardt A, Cazzaniga G, Viehmann S, Valsecchi MG, Ludwig WD, Burci L, Mangioni S, Schrappe M, Riehm H, Lampert F, Basso G, Masera G, Harbott J, Biondi A. Borkhardt A, et al. Among authors: biondi a. Blood. 1997 Jul 15;90(2):571-7. Blood. 1997. PMID: 9226156 Free article.
Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.
Pongers-Willemse MJ, Seriu T, Stolz F, d'Aniello E, Gameiro P, Pisa P, Gonzalez M, Bartram CR, Panzer-Grümayer ER, Biondi A, San Miguel JF, van Dongen JJ. Pongers-Willemse MJ, et al. Among authors: biondi a. Leukemia. 1999 Jan;13(1):110-8. doi: 10.1038/sj.leu.2401245. Leukemia. 1999. PMID: 10049045
Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.
Biondi A, Valsecchi MG, Seriu T, D'Aniello E, Willemse MJ, Fasching K, Pannunzio A, Gadner H, Schrappe M, Kamps WA, Bartram CR, van Dongen JJ, Panzer-Grümayer ER. Biondi A, et al. Leukemia. 2000 Nov;14(11):1939-43. doi: 10.1038/sj.leu.2401922. Leukemia. 2000. PMID: 11069029
Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement.
Jansen MW, Corral L, van der Velden VH, Panzer-Grümayer R, Schrappe M, Schrauder A, Marschalek R, Meyer C, den Boer ML, Hop WJ, Valsecchi MG, Basso G, Biondi A, Pieters R, van Dongen JJ. Jansen MW, et al. Among authors: biondi a. Leukemia. 2007 Apr;21(4):633-41. doi: 10.1038/sj.leu.2404578. Epub 2007 Feb 1. Leukemia. 2007. PMID: 17268512
Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting.
van der Velden VH, Panzer-Grümayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A, Basso G, Schrappe M, Wijkhuijs JM, Konrad M, Bartram CR, Masera G, Biondi A, van Dongen JJ. van der Velden VH, et al. Among authors: biondi a. Leukemia. 2007 Apr;21(4):706-13. doi: 10.1038/sj.leu.2404535. Epub 2007 Feb 8. Leukemia. 2007. PMID: 17287857
1,485 results